Characterization and stability of N-terminally PEGylated rhG-CSF.
about
Site-Specific PEGylation of Therapeutic ProteinsPEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization MethodsInteractions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminusN-terminal protein modification using simple aminoacyl transferase substratesPreparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery.Evaluation of in vitro cytotoxic activity of mono-PEGylated StAP3 (Solanum tuberosum aspartic protease 3) forms.Prevention of benzyl alcohol-induced aggregation of chymotrypsinogen by PEGylation.Hematopoietic properties of granulocyte colony-stimulating factor/immunoglobulin (G-CSF/IgG-Fc) fusion proteins in normal and neutropenic rodents.Pegylation: engineering improved biopharmaceuticals for oncology.Fully Synthetic Granulocyte Colony-Stimulating Factor Enabled by Isonitrile-Mediated Coupling of Large, Side-Chain-Unprotected PeptidesSite-specific PEGylation of lidamycin and its antitumor activity.Pharmacokinetic consequences of pegylation.Site-specific PEGylation enhances the pharmacokinetic properties and antitumor activity of interferon beta-1b.Polypeptide-polymer bioconjugates.Delivery of therapeutic proteins.PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution.Product development issues for PEGylated proteins.Latent cytokines for targeted therapy of inflammatory disorders.PEGylation and its impact on the design of new protein-based medicines.Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study.Protein-polymer therapeutics: a macromolecular perspective.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.N-PEGylation of a reverse turn is stabilizing in multiple sequence contexts, unlike N-GlcNAcylation.Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin.Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study.Purification and analysis of mono-PEGylated HSA by hydrophobic interaction membrane chromatography.Optimization of random PEGylation reactions by means of high throughput screening.Trehalose Glycopolymer Enhances Both Solution Stability and Pharmacokinetics of a Therapeutic Protein.Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue.The Surface of Protein λ6-85 Can Act as a Template for Recurring Poly(ethylene glycol) Structure.Characterization of the PEGylated Functional Upstream Domain Peptide (PEG-FUD): a Potent Fibronectin Assembly Inhibitor with Potential as an Anti-Fibrotic Therapeutic.GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli.Site-Specific Protein PEGylation: Application to Cysteine Analogs of Recombinant Human Granulocyte Colony-Stimulating Factor.Designing Nanocarriers for Drug DeliveryProduction of PEGylated Proteins
P2860
Q26777819-7F7048A1-600F-4929-AB49-2C93F19A2234Q28076027-C06CE582-E69D-4B70-8025-9851FF94649FQ30330466-19C203C4-F235-49F6-A614-066A727C5865Q30406776-C5AE22BE-8545-47E0-A5E6-370D1BE004A5Q31079820-D9009A3E-F598-4B0F-9EE9-761D5655377DQ33783104-C0852C9C-F0D4-43C7-89FB-80A50DC85680Q35062556-A01ED700-5CC9-48AE-ADB1-15E44B2D4828Q35122746-0C623608-4BBF-4C2E-B8C8-C0594377776CQ35200818-89A7D23D-4B3B-480F-ABA4-62D49964B68FQ36198586-439E7226-99E3-4E3A-9FA0-0489BC9A4D29Q36237972-39E53394-4301-43CA-9232-54B6AF0698F0Q36604526-A7630353-9756-4133-A51F-CE2D6BFDB1C1Q37404242-29142A17-4A51-46B4-94FD-3030128119DBQ37659998-9B485700-4248-47DB-B81C-3FF142BADC50Q37668486-016D0A2B-A8EC-4B6E-B5AF-EE5D8B685E42Q37708777-DF568C95-AE48-4D1A-93FF-9537B6BDE56CQ37790702-D1FAF84C-235C-4E83-A4C1-3703B4326F1FQ38167818-BDDE1B73-EB46-4832-A6CA-B15B496229E2Q38269324-E1BF0BF7-0261-4572-8ED1-526962FD6DDBQ38393615-AD0DFD65-3405-4755-B1F5-76E82DAE2366Q38555997-DB155A70-52A9-450F-83A3-A2AD277CE018Q38696361-EEF24D5E-BBEC-461B-BDB2-45640C5948EAQ39251926-6BD5C9C9-ABA1-4033-BFBB-64F11D53D93CQ39479432-522E83BA-EBFC-49F0-952F-6CA9329D12ECQ42069006-62FCAB9F-0090-474F-BBA0-C77E1A16E5E6Q44970118-AB70B934-7401-4C2F-A951-1D2111C51FAEQ45178029-941DF822-82A3-4852-A80B-7B392EBF997BQ46919872-67399DFB-6E1B-4FCB-BF08-3747828B0DF8Q47314051-7FA6DFFC-B6C7-4E0D-B583-B43DC8C3B9CCQ47705981-EA018458-B316-4ACF-A413-D9919A858592Q52716966-F5E121F6-E074-4F53-95DD-9F2FB14FBF9CQ54464834-A697C863-5431-44E7-AC45-BB4D708139E8Q55012956-740B83D3-81D9-4770-A071-6BF03120C031Q57340469-B0104449-145D-4ED2-B67A-29C0892E9976Q57635944-566AABF4-11A4-4FE1-90D0-A76000175145
P2860
Characterization and stability of N-terminally PEGylated rhG-CSF.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Characterization and stability of N-terminally PEGylated rhG-CSF.
@en
Characterization and stability of N-terminally PEGylated rhG-CSF.
@nl
type
label
Characterization and stability of N-terminally PEGylated rhG-CSF.
@en
Characterization and stability of N-terminally PEGylated rhG-CSF.
@nl
prefLabel
Characterization and stability of N-terminally PEGylated rhG-CSF.
@en
Characterization and stability of N-terminally PEGylated rhG-CSF.
@nl
P2093
P356
P1476
Characterization and stability of N-terminally PEGylated rhG-CSF.
@en
P2093
J B Hamburger
M J Treuheit
O B Kinstler
S L Lauren
P304
P356
10.1023/A:1016042220817
P577
1996-07-01T00:00:00Z